Sanuwave Health opened lower at $1.66, compared with its previous close of $1.78. In the last trading session, the stock traded between $1.59 and $1.75. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Sanuwave Health is now worth
$ 2.52
Resulting in a loss of
$ 97.48 (97.48%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.18 (-9.89%)
Day High
$1.75
Day Low
$1.59
Day Open
$1.66
Prev Close
$1.78
Volume
63,618
1W Return
-71.57%
1M Return
-72.61%
3M Return
-70.99%
6M Return
-89.98%
1Y Return
-95.46%
Fundamentals
Market Cap ($ Mn)
14
PE Ratio
19.38
PB Ratio
14.35
PEG Ratio
-
ROE
-
ROCE
-939.77%
EPS (TTM)
$-0.08
Investment Returns
1 Week
-71.57%
1 Month
-72.61%
3 Months
-70.99%
6 Months
-89.98%
9 Months
-93.51%
Financials
Quarterly
All values in $ Mn
9.3
Mar 25
10.2
Jun 25
11.5
Sep 25
13.1
Dec 25
9.6
Mar 26
9.7
Jun 26
Updates
11Nov
Sanuwave Health Q3FY26 Results: Net loss $1.4M, revenue falls 24%
Revenue fell 24% YoY to $8.579 million due to a 74% drop in system unit sales. Net loss widened to $1.4 million compared to prior-year net income driven by non-recurring gains. Company secured a lender waiver for a fixed charge coverage ratio covenant breach. Strategic pivot toward hospital sales targets $27 billion HAPI market to offset mobile care weakness.
Yesterday
7Aug
Sanuwave Health Q2 Results: EPS widens to $(0.08) loss
Sanuwave Health's Q2 results show a worsening financial position, with EPS losses doubling to $(0.08) and sales slipping to $9.739 million. The data reveals a concerning trend where minor revenue declines are leading to significantly larger profit hits.
3mo ago
31Jul
Sanuwave Health Q2 Results: Earnings call scheduled for August 7
Sanuwave Health, Inc. will present Q2 2026 results on August 7, 2026. The call includes dial-in and webcast options, with a replay available until August 21. The company continues to focus on FDA-approved wound care and regenerative medicine technologies.
3mo ago
17Jul
Sanuwave Q2 revenue exceeds revised guidance on record consumable sales
Sanuwave Health reported preliminary Q2 2026 revenue of $9.6–$9.8 million, exceeding the high end of its revised guidance of $8.5–$9.5 million. Despite a 3–5% year-over-year decline, record consumable applicator sales drove the performance. The company continues to address capital sales headwinds through a trade-in program for used systems.
3mo ago
16Jun
Sanuwave Health expects Q2 revenue of $8.5M-$9.5M
Sanuwave Health, Inc. expects Q2 2026 revenue of $8.5M-$9.5M, missing prior guidance from May 13. The company specializes in FDA-cleared directed energy systems for advanced wound care.
